Clinically, elevated tumor MMP-9 associates with poorer outcomes in early-stage disease, aligning with the concern that tamoxifen-selected phenotypes with higher MMP-9 activity could contribute to adverse biology in a subset of patients [132]. The gene discussed is MMP9; the disease is neoplasm.